Dr Seoane talks to ecancertv at ESMO 2016 about modelling cell lines and determining biomarkers for better prognosis.
Considering the pathways through which cancers develop insenstivity to different therapies, Dr Seoane highlights the need for greater understanding and proactive prevention of resistance with novel treatments and combination therapy.
